A Study of Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)
A Study of Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)
To look at the ability of LY2127399 to reduce magnetic resonance imaging (MRI) lesions at 12,
 16, 20, and 24 weeks compared to placebo.
Inclusion Criteria:

 -  18 through 64 years of age diagnosed with RRMS, who can walk without aid or rest for
 at least 200 meters (approximately 1/10 of a mile).

 -  Women who can become pregnant must use birth control.

 Exclusion Criteria:

 -  Have had a live vaccination within 12 weeks before randomization, or intend to have a
 live vaccination during the course of the study.

 -  Have had had recent surgery or are scheduled to have surgery during the study.

 -  Are immunocompromised or have evidence of active infection [such as hepatitis,
 tuberculosis or, human immunodeficiency virus (HIV)].

 -  Have been on certain drugs that are being studied for RRMS or have recently received
 prescription drugs to treat RRMS.

 -  Have had a recent serious infection.

 -  Have serious or uncontrolled illnesses other than RRMS.

 -  Have clinically significant blood test values.

 -  Have multiple or severe drug allergies.

 -  Have contraindications for MRI "scanning" or claustrophobia (fear of an enclosed
 space) that cannot be managed.